Alvimopan is a peripherally acting mu-opioid receptor (PAM-OR) antagonist that has been studied for the treatment of opioid-induced bowel dysfunction. Alvimopan counteracts the effects of opioids on gastrointestinal motility and secretion. The drug is available as a capsule to take by mouth and has been evaluated in opioid-induced constipation.